J&J rises about 1% after AbbVie myeloma drug 74% response
Johnson & Johnson rose roughly 1% to $277.955 Thursday afternoon after AbbVie’s experimental multiple-myeloma drug etentamig showed a 74% response rate, lowering the risk of disease progression or death.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.